The efficacy and safety profile of lisdexamfetamine dimesylate, a prodrug of d-amphetamine, for the treatment of attention-deficit/hyperactivity disorder in children and adults

Clinical Therapeutics

Volumn 31, Issue 1, 2009, Pages 142-176

  Najib, Jadwiga ^a,b  

^a LONG ISLAND UNIVERSITY   (United States)

^b ST LUKE S ROOSEVELT HOSPITAL CENTER   (United States)

Author keywords

attention deficit hyperactivity disorder; lisdexamfetamine dimesylate; NRP104; NRP104 201; NRP104 301; NRP104 302; NRP104 303; stimulant

Indexed keywords

ADRENERGIC RECEPTOR BLOCKING AGENT; ADRENERGIC RECEPTOR STIMULATING AGENT; AMFEBUTAMONE; AMITRIPTYLINE; AMMONIUM CHLORIDE; AMPHETAMINE; AMPHETAMINE ASPARTATE; ATOMOXETINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BICARBONATE; CLONIDINE; DESIPRAMINE; DEXAMPHETAMINE; DEXMETHYLPHENIDATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROPROPOXYPHENE; DISODIUM HYDROGEN PHOSPHATE; GUANFACINE; IMIPRAMINE; LISDEXAMFETAMINE; METHYLPHENIDATE; MODAFINIL; MONOAMINE OXIDASE INHIBITOR; NORTRIPTYLINE; PETHIDINE; PLACEBO; TRICYCLIC ANTIDEPRESSANT AGENT; UNCLASSIFIED DRUG; UNINDEXED DRUG; VENLAFAXINE; VERATRUM ALKALOID;

ANGER; ANOREXIA; ANXIETY DISORDER; ARTICLE; ATTENTION DEFICIT DISORDER; BLOOD PRESSURE; BLURRED VISION; BRUXISM; CLINICAL EFFECTIVENESS; CLINICAL STUDY; CLINICAL TRIAL; COMPARATIVE STUDY; CONFUSION; COUGHING; DECREASED APPETITE; DEPRESSION; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DIZZINESS; DRUG COST; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; DYSTONIA; EDUCATION; EUPHORIA; EVENING DOSAGE; FASCICULATION; FEVER; HALLUCINATION; HEADACHE; HEALTH PRACTITIONER; HEART PALPITATION; HEART RATE; HUMAN; HYPERACTIVITY; HYPERKINESIA; HYPERTENSION; INFLUENZA; INSOMNIA; INTERVENTION STUDY; IRRITABILITY; LOGORRHEA; MEDICAL INFORMATION; MEDICAL LIABILITY; MEDLINE; MOOD DISORDER; MORNING DOSAGE; NAUSEA; NONHUMAN; NOSE CONGESTION; OPEN STUDY; PARENT; PEDIATRICS; PHARMACODYNAMICS; PREGNANCY; PSYCHOLOGICAL ASPECT; RATING SCALE; RHINOPHARYNGITIS; SEIZURE; SIDE EFFECT; SINUS TACHYCARDIA; SOCIAL ASPECT; SOMNOLENCE; TACHYCARDIA; THERAPY EFFECT; THORAX PAIN; TIC; TREMOR; UPPER ABDOMINAL PAIN; UPPER RESPIRATORY TRACT INFECTION; VOMITING; WEIGHT REDUCTION; XEROSTOMIA;

ADULT; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CENTRAL NERVOUS SYSTEM STIMULANTS; CHILD; CLINICAL TRIALS AS TOPIC; DEXTROAMPHETAMINE; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; PRODRUGS; SUBSTANCE-RELATED DISORDERS;

EID: 60449118372     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2009.01.015     Document Type: Article

References (100)

1. American Academy of Pediatrics. Clinical practice guideline: Diagnosis and evaluation of the child with attention-deficit/ hyperactivity disorder. Pediatrics. 105 (2000) 1158-1170
2. Faraone S.V., Sergeant J., Gillberg C., and Biederman J. The worldwide prevalence of ADHD: Is it an American condition?. World Psychiatry. 2 (2003) 104-113
3. National Health Interview Survey (NHIS): Vital and Health Statistics Series 10, Number 206. Attention Deficit Disorder and Learning Disability: United States, 1997-1998 (May 2002), Centers for Disease Control and Prevention, National Center for Health Statistics, Bethesda, Md Publication no. (PHS) 2002-1534
4. National Health Interview Survey (NHIS): Vital and Health Statistics Series 10, Number 234. Summary Health Statistics for US Children: National Health Interview Survey, 2006 (September 2007), Centers for Disease Control and Prevention, National Center for Health Statistics, Bethesda, Md
5. Polanczyk G., de Lima M.S., Horta B.L., et al. The worldwide prevalence of ADHD: A systematic review and metaregression analysis. Am J Psychiatry. 164 (2007) 942-948
6. Arnold L.E. Sex differences in ADHD: Conference summary. J Abnorm Child Psychol. 24 (1996) 555-569
7. Wolraich M.L., Hannah J.N., Pin nock T.Y., et al. Comparison of diagnostic criteria for attention-deficit hyperactivity disorder in a county-wide sample. J Am Acad Child Adolesc Psychiatry. 35 (1996) 319-324
8. Greene R.W., Biederman J., Faraone S.V., et al. Social impairment in girls with ADHD: Patterns, gender comparisons, and correlates. J Am Acad Child Adolesc Psychiatry 40 (2001) 704-710
9. Cohen P., Cohen J., Kasen S., et al. An epidemiological study of disorders in late childhood and adolescence-I. Age- and gender-specific prevalence. J Child Psychol Psychiatry. 34 (1993) 851-867
10. Kessler R.C., Adler L., Barkley R., et al. The prevalence and correlates of adult ADHD in the United States: Results from the National Comorbidity Survey Replication. Am J Psychiatry. 163 (2006) 716-723
11. Richters J.E., Arnold L.E., Jensen P.S., et al. NIMH collaborative multiSite multimodal treatment study of children with ADHD: I. Background and rationale. J Am Acad Child Adolesc Psychiatry. 34 (1995) 987-1000
12. American Academy of Child & Adolescent Psychiatry. New medication guide available for parents on treating attention-deficit/hyperactivity disorder: Helping parents help their kids. http://parentsmedguide.org/07_75ADHDMedGuideNewsRelease.pdf Accessed July 30, 2008.
13. Biederman J. Pharmacotherapy for attention-deficit/ hyperactivity disorder (ADHD) decreases the risk for substance abuse: Findings from a longitudinal follow-up of youths with and without ADHD. J Clin Psychiatry. 64 Suppl 11 (2003) 3-8
14. Pelham W.E., Foster E.M., and Robb J.A. The economic impact of attention-deficit/hyperactivity disorder in children and adolescents. J Pediatr Psychol. 32 (2007) 711-727
15. Berquin P.C., Geidd J.N., Jacobsen L.K., et al. Cerebellum in attention-deficit hyperactivity disorder: A morphometric M RI study. Neurology. 50 (1998) 1087-1093
16. Mick E., Biederman J., Prince J., et al. Impact of low birth weight on attention-deficit hyperactivity disorder. J Dev Behav Pediatr. 23 (2002) 16-22
17. Max J.E., Arndt S., Castillo C.S., et al. Attention-deficit hyperactivity symptomatology after traumatic brain injury: A prospective study. J Am Acad Child Adolesc Psychiatry. 37 (1998) 841-847
18. Braun J.M., Kahn R.S., Froehlich T., et al. Exposures to environmental toxicants and attention deficit hyperactivity disorder in U.S. children. Environ Health Perspect. 114 (2006) 19041909
19. Bellinger D., Hu H., Titlebaum L., and Needleman H.L. Attentional correlates of dentin and bone lead levels in adolescents. Arch Environ Health. 49 (1994) 98-105
20. Needleman H.L. Childhood lead poisoning. Curr Opin Neurol. 7 (1994) 187-190
21. Mick E., Biederman J., Faraone S.V., et al. Case-control study of attention-deficit hyperactivity disorder and maternal smoking, alcohol use, and drug use during pregnancy. J Am Acad Child Adolesc Psychiatry. 41 (2002) 378-385
22. Linnet K.M., Dalsgaard S., Obel C., et al. Maternal lifestyle factors in pregnancy risk of attention hyperactivity disorder and associated behaviors: Review of the current evidence. Am J Psychiatry. 160 (2003) 1028-1040
23. Phszka S., and the AACAP Work Group on Quality Issues. Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 46 (2007) 894-921
24. Godefroy O., and Rousseaux M. Divided and focused attention in patients with lesions of the prefrontal cortex. Brain Cogn. 30 (1996) 155-174
25. Faraone S.V., Perils R.H., Doyle A.E., et al. Molecular genetics of attention-deficit/hyperactivity disorder. Biol Psychiatry. 57 (2005) 1313-1323
26. Faraone S.V. Etiology and pathophysiology of adult attention-deficit/ hyperactivity disorder. Primary Psychiatry. 11 (2004) 28-40
27. Pauls D.L. The genetics of attention-deficit/hyperactivity disorder. Biol Psychiatry. 57 (2005) 1310-1312
28. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR) (2000), American Psychiatric Association, Washington, DC
29. Faraone S.V., Biederman J., Spencer T., et al. Diagnosing adult attention deficit hyperactivity disorder: Are late onset and subthreshold diagnoses valid?. Am J Psychiatry. 163 (2006) 1720-1729
30. McGough J.J., and Barkley R.A. Diagnostic controversies in adult attention deficit hyperactivity disorder. Am J Psychiatry. 161 (2004) 1948-1956
31. Brown R.T., Amler R.W., Freeman W.S., et al., the American Academy of Pediatrics Committee on Quality Improvement and the American Academy of Pediatrics Subcommittee on Attention-Deficit Hyperactivity Disorder. Treatment of attention-deficit/hyperactivity disorder: Overview of the evidence. Pediatrics 115 (2005) e749-e757
32. American Academy of Pediatrics Subcommittee on Attention-Deficit/ Hyperactivity Disorder and Committee on Quality Improvement. Clinical practice guideline: Treatment of the school-aged child with attention-deficit/hyperactivity disorder. Pediatrics. 108 (2001) 1033-1044
33. Phszka S.R., Crismon M.L., Hughes C.W., et al., the Texas Consensus Conference Panel on Pharmacotherapy of Childhood Attention. Deficit Hyperactivity Disorder. The Texas Children's Medication Algorithm Project: Revision of the algorithm for the pharmacotherapy of attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 45 (2006) 642-657
34. Biederman J., and Faraone S.V. Attention-deficit hyperactivity disorder. Lancet 367 (2006) 210 published correction appears in
35. Biederman J., and Faraone S.V. Attention-deficit hyperactivity disorder. Lancet 366 (2005) 237-248
36. Dopheide J.A. ASHP therapeutic position statement on the appropriate use of medications in the treatment of attention-deficit/hyperactivity disorder in pediatric patients. Am J Health Syst Pharm. 62 (2005) 1502-1509
37. Wilens T.E., and Spencer T.J. The stimulants revisited. Child Adolesc Psychiatr Clin N Am. 9 (2000) 573-603
38. Olfson M. New options in the pharmacological management of attention-deficit/hyperactivity disorder. Am J Manag Care. 10 Suppl 4 (2004) S117-S124
39. Wilens T.E., Biederman J., and Spencer T.J. Attention deficit/hyperactivity disorder across the lifespan. Annu Rev Med. 53 (2002) 113-131
40. James R.S., Sharp W.S., Bastain T.M., et al. Double-blind, placebo-controlled study of single-dose amphetamine formulations in ADHD. J Am Acad Child Adolesc Psychiatry. 40 (2001) 1268-1276
41. Arnold L.E. Methylphenidate vs. amphetamine: Comparative review. J Atten Disord. 3 (2000) 200-211
42. Faraone S.V. Understanding the effect size of ADHD medications: Implications for clinical care. Medscape Psychiatry Mental Health 8 2 (2003). http://www.medscape.com/viewarticle/461543 Accessed September 1, 2008
43. Smoot L.C., Boothby L.A., and Gillett R.C. Clinical assessment and treatment of ADHD in children. Int J Clin Pract. 61 (2007) 1730-1738
44. Spencer T.J. ADHD treatment across the life cycle. J Clin Psychiatry. 65 Suppl 3 (2004) 22-26
45. Spencer T., Biederman J., Wilens T., et al. Pharmacotherapy of attention-deficit hyperactivity disorder across the life cycle. J Am Acad Child Adolesc Psychiatry. 35 (1996) 409-432
46. Vyvanse (lisdexamfetamine dimesylate) [package insert] (2008), Shire US Inc, Wayne, Pa. Accessed September 1, 2008 http://www.vyvanse.com/index-child.asp?WT.srch=1&src=1&mid=V0008 03&tid=1489731&KEYWORD=vyvanse&gclid=CIH_96fMvpcCFQObFQodCXo fS
47. Markowitz J.S., Straughn A.B., and Patrick K.S. Advances in the pharmacotherapy of attention-deficit-hyperactivity disorder: Focus on methylphenidate formulations. Pharmacotherapy. 23 (2003) 1281-1299
48. Solanto M.V. Neuropsychopharma-cological mechanisms of stimulant drug action in attention-deficit hyperactivity disorder: A review and integration. Behav Brain Res. 94 (1998) 127-152
49. Krishnan S., and Montcrief S. Toxicity profile of hsdexamfetamine dimesylate in three independent rat toxicology studies. Basic Clin Pharmacol Toxicol. 101 (2007) 231-240
50. Dexednne (dextroamphetamine sulfate) capsule and tablets [package insert] (2006), Glaxo Smith Kline, Research Triangle Park, NC. http://www.fda.gov/medWatch/SAFETY/2006/Dexedrine_Pl.pdf Accessed September 1, 2008
51. Krishnan S., and Moncrief S. An evaluation of the cytochrome p450 inhibition potential of hsdexamfetamine in human liver microsomes. Drug Metab Dispos. 35 (2007) 180-184
52. Biederman J., Boellner S.W., Childress A., et al. Lisdexamfetamine dimesy-late and mixed amphetamine salts extended-release in children with ADHD: A double-blind, placebo-controlled, crossover analog classroom study. Biol Psychiatry. 62 (2007) 970-976
53. Krishnan S.M., and Stark J.G. Multiple daily-dose pharmacokinetics of hsdexamfetamine dimesylate in healthy adult volunteers. Curr Med Res Opm. 24 (2008) 33-40
54. Krishnan S., and Zhang Y. Relative bioavailability of hsdexamfetamine 70-mg capsules in fasted and fed healthy adult volunteers and in solution: A single-dose, crossover pharmacokinetic study. J Clin Pharmacol. 48 (2008) 293-302
55. Jasinski D., and Krishnan S. Pharmacokinetics of oral hsdexamfetamine dimesylate (LDX; NRP104) vs d-amphetamine in healthy adults with a history of stimulant abuse. Presented at: 2006 US Psychiatric and Mental Health Congress. New Orleans, La (November 17-19, 2006)
56. Krishnan S., Ermer J.C., Kehner G., et al. Effect of food on hsdexamfetamine dimesylate (LDX; NRP104) pharmacokinetics. Presented at: 2006 US Psychiatric and Mental Health Congress. New Orleans, La (November 17-19, 2006)
57. Moncnef S., Curtiss S., and Krishnan S. Pharmacokinetics of NRP 104 (hsdexamfetamine dimesylate) following administration of a single intranasal, intravenous, or oral dose in rats. Presented at: 58th Institute on Psychiatric Services Annual Meeting. New York, NY (October 6, 2006)
58. Jasinski D., and Krishnan S. Abuse liability of intravenous hsdexamfetamine dimesylate (LDX; NRP104). Presented at: The US Psychiatric and Mental Health 19th Annual Congress. New York, NY (November 17, 2006)
59. Lisdexamfetamine dimesylate (Vyvanse) for ADHD. Med Lett Drugs Ther. 49 (2007) 58-59
60. Adderall X.R. (mixed amphetamine salts extended release) capsules [package insert] (2007), Shire US Inc, Wayne, Pa
61. McGough J.J., Biederman J., Green-hill L.L., et al. Pharmacokinetics of SL1381 (ADDERALL XR), an extended-release formulation of Adderall. J Am Acad Child Adolesc Psychiatry. 42 (2003) 684-691
62. Shojaei A., Ermer J.C., and Krishnan S. Lisdexamfetamine dimesylate as a treatment for ADHD: Dosage formulation and pH effects. Presented at: 16th Annual Meeting of the American Psychiatric Association. San Diego, Calif. (May 19, 2007)
63. Barry R.J., and Clarke A.R. Lisdexamfetamine: A viewpoint. Pediatr Drugs. 9 (2007) 136-138
64. Biederman J., Krishnan S., Zhang Y., et al. Efficacy and tolerabihty of hsdexamfetamine dimesylate (NRP-104) in children with attention-deficit/hyperactivity disorder: A Phase III, multicenter, randomized, double-blind, forced-dose, parallel-group study. Clin Ther. 29 (2007) 450-463
65. Findling R.L., Childress A.C., Krishnan S., and McGough J.J. Long-term effectiveness and safety of hsdexamfetamine dimesylate in school-aged children with attention-deficit/hyperactivity disorder. CNS Spectr. 13 (2008) 614-620
66. Adler L., Goodman D.W., Kolhns S.H., et al. Efficacy and safety of hsdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder. Presented at: 54th Annual Meeting of the American Academy of Child & Adolescent Psychiatry. Boston, Mass. (October 25, 2007)
67. Niebler G., Wilen T.E., Weisler R., et al. Evaluation of cardiovascular effects of hsdexamfetamine dimesylate treatment in adults with attention-deficit/hyperactivity disorder. Presented at: 161 st Annual Meeting of the American Psychiatric Association. Washington, DC (May 3-8, 2008)
68. Goodman D., Adler L., Weisler R., et al. Effect of hsdexamfetamine dimesylate on sleep quality in adults with attention-deficit/hyperactivity disorder. Presented at: 161st Annual Meeting of the American Psychiatric Association. Washington, DC (May 3-8, 2008)
69. Wigal S.B., Gupta S., Guinta D., and Swanson J.M. Reliability and validity of the SKAMP rating scale in a laboratory school setting. Psychopharmacol Bull. 34 (1998) 47-53
70. Swanson J., Wigal S., Greenhill L., et al. Objective and subjective measures of the pharmacodynamic effects of Adderall in the treatment of children with ADHD in a controlled laboratory classroom setting. Psychopharmacol Bull. 34 (1998) 55-60
71. Guy W. Clinical Global Impression (CGI). ECDEU Assessment Manual for Psychopharmacology (1976), US Dept of Health, Education, and Welfare, Rockville, Md 218-222 Alcohol, Drug Abuse, and Mental Health Administration, NIMH Psychopharmacology Research Branch, Division of Extramural Research Programs
72. DuPaul G.J., Power T.J., Anastopoulos A.D., and Reid R. The ADHD Rating Scale-IV: Checklists, Norms, and Clinical Interpretation (1998), Guilford Press, New York, NY
73. Faries D.E., Yalcin I., Harder D., and Heili-genstem J.H. Validation ofthe ADHD Rating Scale as a clinician administered and scored instrument. J Atten Disord. 5 (2001) 107-115
74. Conners C.K., Sitarenios G., Parker J.D., and Epstein J.N. The revised Conners' Parent Rating Scale (CPRS-R): Factor structure, reliability, and criterion validity. J Abnorm Child Psychol. 26 (1998) 257-268
75. Faraone S.V., Biederman J., Spencer T.J., and Aleardi M. Comparing the efficacy of medications for ADHD using metaanalysis. Med Cen Med. 8 (2006) 4
76. Blick S.K., and Keating G.M. Lisdexamfetamine. Pediatr Drugs. 9 (2007) 129-135 discussion
77. Blick S.K., and Keating G.M. Lisdexamfetamine. Pediatr Drugs. 9 (2007) 136-138
78. Biederman J., Lopez F.A., Boellner S.W., and Chandler M.C. A randomized, double-blind, placebo-controlled, parallel-group study of SLI381 (Adderall XR) in children with attention-deficit/hyperactivity disorder. Pediatrics 110 (2002) 258-266
79. Buysse D.J., Reynolds III C.F., Monk T.H., et al. The Pittsburgh Sleep Quality Index: A new instrument for psychiatric practice and research. Psychiatry Res. 28 (1989) 193-213
80. An open-label study of NRP104 in adults with attention deficit hyper-activity disorder (ADHD) [Chnical-Trials.govldentifier:NCT00337285]. http://www.clinicaltrials.gov/ct2/show/NCT00337285?term=NCT00337285& rank=1 Accessed July 30, 2008
81. Philipsen A., Hornyak M., and Riemann D. Sleep and sleep disorders in adults with attention deficit/hyperactivity disorder. Sleep Med Rev. 10 (2006) 399-405
82. Spiller H.A., Griffith J.R., Anderson D.L., et al. Poison centers detect an unexpectedly frequent number of adverse drug reactions to lisdexamfetamine. Ann Pharmacother. 42 (2008) 1142-1143
83. Phelan K.M. Summary of psychiatric and neurological adverse events fromjune 2005. One-year post pediatric exclusivity reviews of Concerta and other methylphenidate products. www.fda.gov/ohrms/dockets/ac/06/briefing/2006-4210b_09_01_Methsummary.pd f Accessed August 23, 2008
84. Department of Justice. Drug Enforcement Administration. 21 CFR Part 1308 [Docket No. DEA-301F] Schedules of Controlled Substances: Placement of lisdexamfetamine into Schedule II. Federal Register 72 (2007) 24532-24534. http://www.deadiversion.usdoj.gov/fed_regs/rules/2007/fr0503.htm Accessed August 30, 2008
85. Jasinski D., and Krishnan S. A double-blind, randomized, placebo- and active-controlled, 6-period crossover study to evaluate the hkeabihty, safety, and abuse potential of lisdexamfetamine dimesylate (LDX) in adult stimulant abusers. Presented at: US Psychiatric and Mental Health Congress. New Orleans, La. (November 17-19, 2006)
86. Red Book: Pharmacy's Fundamental Reference, 2008 Edition (April 2008), Thomson Healthcare, Montvale, NJ
87. Vetter V.L., Elia J., Erickson C., et al. for the American Heart Association Council on Cardiovascular Disease in the Young Congenital Cardiac Defects Committee and the American Heart Association Council on Cardiovascular Nursing. Cardiovascular monitoring of children and adolescents with heart disease receiving stimulant drugs: A scientific statement from the American Heart Association Council on Cardiovascular Disease in the Young Congenital Cardiac Defects Committee and the Council on Cardiovascular Nursing. Circulation 117 (2008) 24072423
88. Nissen S.E. ADHD drugs and cardiovascular risk. N Engl J Med. 354 (2006) 1445-1448
89. Perrin J.M., Friedman R.A., and Knilans T.K. Cardiovascular monitoring and stimulant drugs for attention-deficit/hyperactivity disorder. Pediatrics 122 (2008) 451-453
90. O'Keefe L. ECGs for all ADHD patients? AAP-AHA release joint 'clarification' on AHA recommendation. AAP News 29 (2008) 1
91. Pliszka S.R., Matthews T.L., Braslow K.J., and Watson M.A. Comparative effects of methylphenidate and mixed salts amphetamine on height and weight in children with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 45 (2006) 520-526
92. Poulton A. Growth on stimulant medication; clarifying the confusion: A review. Arch Dis Child. 90 (2006) 801-806
93. Hellander M. Medication-induced mania: Ethical issues and the need for more research. J Child Adolesc Psychopharmacol. 13 (2003) 199
94. Gelperin K., and Phelan K. Psychiatric adverse events associated with drug treatment of ADHD: Review of postmarketing safety data. FDA Report PID D050243. http://www.fda.gov/ohrms/dockets/ac/06/bnefing/2006-4210b_11_01_AdverseE vents.pdf Accessed September 1, 2008
95. Mosholder A. Psychiatric adverse events in clinical trials of drugs for attention deficit hyperactivity disorder (ADHD). FDA Report PID D060163. http://www.fda.gov/ohrms/dockets/ac/06/bnefing/2006-4210b_10_01_Mosholde r.pdf Accessed August 23, 2008
96. Phelan K.M. One year post-pediatnc exclusivity postmarketing adverse event review: FDA Report PID. http://www.fda.gov/ohrms/dockets/ac/06/briefing/2006-4210b_05_02_Adderal lSafetyReview.pdf Accessed August 23, 2008
97. Grcevich S. Lisdexamfetamine: A viewpoint. Pediatric Drugs 9 (2007) 136
98. Wilens T.E., Gignac M., Swezey T.J., et al. Characteristics of adolescents and young adults with ADHD who divert or misuse their prescribed medications. J Am Acad Child Adolesc Psychiatry 45 (2006) 408-414
99. White B.P., Becker-Blease K.A., and Grace-Bishop K. Stimulant medication use, misuse, and abuse in an undergraduate and graduate student sample. J Am Coll Health 54 (2006) 261-268
100. Teter C.J., McCabe S.E., LaGrange K., et al. Illicit use of specific prescription stimulants among college students: Prevalence, motives, and routes of administration. Pharmacotherapy 26 (2006) 1501-1510